620 related articles for article (PubMed ID: 9699662)
21. Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma.
Mihara K; Yanagihara K; Takigahira M; Kitanaka A; Imai C; Bhattacharyya J; Kubo T; Takei Y; Yasunaga S; Takihara Y; Kimura A
Br J Haematol; 2010 Oct; 151(1):37-46. PubMed ID: 20678160
[TBL] [Abstract][Full Text] [Related]
22. Antibody-mediated specific binding and cytotoxicity of liposome-entrapped doxorubicin to lung cancer cells in vitro.
Ahmad I; Allen TM
Cancer Res; 1992 Sep; 52(17):4817-20. PubMed ID: 1511445
[TBL] [Abstract][Full Text] [Related]
23. Expression and purification of two anti-CD19 single chain Fv fragments for targeting of liposomes to CD19-expressing cells.
Cheng WW; Das D; Suresh M; Allen TM
Biochim Biophys Acta; 2007 Jan; 1768(1):21-9. PubMed ID: 17046711
[TBL] [Abstract][Full Text] [Related]
24. Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models.
Shah SA; Halloran PM; Ferris CA; Levine BA; Bourret LA; Goldmacher VS; Blättler WA
Cancer Res; 1993 Mar; 53(6):1360-7. PubMed ID: 7680284
[TBL] [Abstract][Full Text] [Related]
25. Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3 x CD19 tandem diabody, and CD28 costimulation.
Cochlovius B; Kipriyanov SM; Stassar MJ; Schuhmacher J; Benner A; Moldenhauer G; Little M
Cancer Res; 2000 Aug; 60(16):4336-41. PubMed ID: 10969772
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy.
Ghetie MA; May RD; Till M; Uhr JW; Ghetie V; Knowles PP; Relf M; Brown A; Wallace PM; Janossy G
Cancer Res; 1988 May; 48(9):2610-7. PubMed ID: 2451562
[TBL] [Abstract][Full Text] [Related]
27. In vitro cytotoxic study of immunoliposomal doxorubicin targeted to human CD34(+) leukemic cells.
Carrion C; de Madariaga MA; Domingo JC
Life Sci; 2004 Jun; 75(3):313-28. PubMed ID: 15135652
[TBL] [Abstract][Full Text] [Related]
28. Development of pH-sensitive liposomes that efficiently retain encapsulated doxorubicin (DXR) in blood.
Ishida T; Okada Y; Kobayashi T; Kiwada H
Int J Pharm; 2006 Feb; 309(1-2):94-100. PubMed ID: 16364578
[TBL] [Abstract][Full Text] [Related]
29. Tumor targeting of vincristine by mBAFF-modified PEG liposomes in B lymphoma cells.
Zhang L; Gao H; Chen L; Wu B; Zheng Y; Liao R; Jiang Y; He F
Cancer Lett; 2008 Sep; 269(1):26-36. PubMed ID: 18534744
[TBL] [Abstract][Full Text] [Related]
30. Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage.
Shmeeda H; Tzemach D; Mak L; Gabizon A
J Control Release; 2009 Jun; 136(2):155-60. PubMed ID: 19331844
[TBL] [Abstract][Full Text] [Related]
31. A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo.
Ward E; Mittereder N; Kuta E; Sims GP; Bowen MA; Dall'Acqua W; Tedder T; Kiener P; Coyle AJ; Wu H; Jallal B; Herbst R
Br J Haematol; 2011 Nov; 155(4):426-37. PubMed ID: 21902688
[TBL] [Abstract][Full Text] [Related]
32. In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach.
Iden DL; Allen TM
Biochim Biophys Acta; 2001 Aug; 1513(2):207-16. PubMed ID: 11470092
[TBL] [Abstract][Full Text] [Related]
33. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
Park JW; Hong K; Kirpotin DB; Colbern G; Shalaby R; Baselga J; Shao Y; Nielsen UB; Marks JD; Moore D; Papahadjopoulos D; Benz CC
Clin Cancer Res; 2002 Apr; 8(4):1172-81. PubMed ID: 11948130
[TBL] [Abstract][Full Text] [Related]
34. Anti-MUC-1 immunoliposomal doxorubicin in the treatment of murine models of metastatic breast cancer.
Moase EH; Qi W; Ishida T; Gabos Z; Longenecker BM; Zimmermann GL; Ding L; Krantz M; Allen TM
Biochim Biophys Acta; 2001 Feb; 1510(1-2):43-55. PubMed ID: 11342146
[TBL] [Abstract][Full Text] [Related]
35. Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells.
Eliaz RE; Szoka FC
Cancer Res; 2001 Mar; 61(6):2592-601. PubMed ID: 11289136
[TBL] [Abstract][Full Text] [Related]
36. A metronomic schedule of cyclophosphamide combined with PEGylated liposomal doxorubicin has a highly antitumor effect in an experimental pulmonary metastatic mouse model.
Shiraga E; Barichello JM; Ishida T; Kiwada H
Int J Pharm; 2008 Apr; 353(1-2):65-73. PubMed ID: 18155369
[TBL] [Abstract][Full Text] [Related]
37. Potentiation by interleukin 2 of Burkitt's lymphoma therapy with anti-pan B (anti-CD19) monoclonal antibodies in a mouse xenotransplantation model.
Vuist WM; v Buitenen F; de Rie MA; Hekman A; Rümke P; Melief CJ
Cancer Res; 1989 Jul; 49(14):3783-8. PubMed ID: 2472198
[TBL] [Abstract][Full Text] [Related]
38. Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys.
Sapra P; Stein R; Pickett J; Qu Z; Govindan SV; Cardillo TM; Hansen HJ; Horak ID; Griffiths GL; Goldenberg DM
Clin Cancer Res; 2005 Jul; 11(14):5257-64. PubMed ID: 16033844
[TBL] [Abstract][Full Text] [Related]
39. Combining adoptive cellular and immunocytokine therapies to improve treatment of B-lineage malignancy.
Singh H; Serrano LM; Pfeiffer T; Olivares S; McNamara G; Smith DD; Al-Kadhimi Z; Forman SJ; Gillies SD; Jensen MC; Colcher D; Raubitschek A; Cooper LJ
Cancer Res; 2007 Mar; 67(6):2872-80. PubMed ID: 17363611
[TBL] [Abstract][Full Text] [Related]
40. Cure of SCID mice bearing human B-lymphoma xenografts by an anti-CD74 antibody-anthracycline drug conjugate.
Griffiths GL; Mattes MJ; Stein R; Govindan SV; Horak ID; Hansen HJ; Goldenberg DM
Clin Cancer Res; 2003 Dec; 9(17):6567-71. PubMed ID: 14695162
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
